Clinical trials: Macular Degeneration
Age-related Macular Degeneration
Macular Degeneration and Aging Study
The purpose of this randomized trial is to examine the effectiveness of a psycho-social "Preventive Problem Solving Intervention" on emotional well-being, change in future outlook, and vision functioning in 250 Age-related…
- Trial name
- MADAS (NCT02224963)
- Testing
- Preventive Problem-Solving Training, Life and Health Review
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- University of Rochester
Neovascular (Wet) AMD
Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
This is a randomized, double-masked, parallel-group, multicenter, therapeutic equivalence study evaluating the efficacy, safety, and immunogenicity of AVT06 compared with Eylea in subjects with neovascular (wet) AMD.
- Trial name
- ALVOEYE (NCT05155293)
- Testing
- AVT06 (proposed aflibercept biosimilar), Eylea® (Aflibercept)
- Where
- 6 sites in Czechia, Georgia and 3 more
- Volunteers
- 413 people
- Sponsor
- Alvotech Swiss AG
Complement Mediated Diseases
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the complement inhibitor AMY-101.
- Trial name
- NCT03316521
- Testing
- AMY-101
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Amyndas Pharmaceuticals S.A.
Stargardt Disease
An Observational Study in Children and Adults With Stargardt Disease
This multicenter, prospective, longitudinal, observational study in approximately 80 subjects with Stargardt disease secondary to biallelic mutations in the ABCA4 gene (STGD1) aims to evaluate prognostic factors of disease…
- Trial name
- NCT06591806
- Where
- 2 sites in United States, Norway
- Volunteers
- 80 people
- Sponsor
- AAVantgarde Bio Srl
Macular Degeneration
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until…
- Trial name
- NCT00088192
- Testing
- pegaptanib sodium
- Where
- 20 sites in United States
- Sponsor
- Eyetech Pharmaceuticals
Vision Disorders
Usability of the Software MacuFix for the Categorization of Metamorphopsia
The usability of a novel test to categorize a distorted visual impression (metamorphopsia) is examined with the questionnaire "SUS"
- Trial name
- MacuFix (NCT04347564)
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Augenheilkunde Lindenthal
Subretinal Hemorrhage, Age-Related Macular Degeneration
Robotic Subretinal tPA Injection Study
In the RoTIS study, the investigators would like to test the robotic stabilizer for the subretinal injection of tPA in patients with subretinal hemorrhage during standard-of-care surgery.
- Trial name
- RoTIS (NCT06347107)
- Testing
- Robotic subretinal tPA injection
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Age-related Macular Degeneration
CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography
CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
- Trial name
- CAPTAIN (NCT00500344)
- Testing
- Lucentis (ranibizumab)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Washington University School of Medicine
Age-Related Macular Degeneration, Diabetic Retinopathy
Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations
In this study, participants will be imaged using two Optical Coherence Tomography (OCT) devices: device N, a standard conventional OCT device with an invention (comfortable chin and forehead rest that can be adjusted to fit each…
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Central Serous Chorioretinopathy, Glaucoma
- Trial name
- NCT05686421
- Testing
- OCT Imaging Using Device N, OCT Imaging Using Device C
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Age Related Macular Degeneration
Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration
This is a pilot study to evaluate the safety of the Model WA-NG telescope prosthesis in patients with bilateral moderate to profound central vision impairment due to end-stage age-related macular degeneration.
- Trial name
- NCT01731964
- Testing
- Telescope prosthesis, WA-NG Telescope Prothesis
- Where
- Israel
- Sponsor
- VisionCare, Inc.
Dry Macular Degeneration
BioCurrent Electrical Stimulation for the Treatment of Dry ARMD
This study evaluates the treatment of Dry Macular Degeneration and the resulting change in vision with a very, very low current that is similar to what occurs in the body naturally.
- Trial name
- NCT02699216
- Testing
- Electrical Stimulation of the Retina
- Volunteers
- healthy volunteers welcome
- Sponsor
- DuBois Vision Clinic
Age-related Macular Degeneration
Efficacy of Laser Acupuncture on Zanzhu (BL02) for Dry Age-related Macular Degeneration
This study is to see if laser acupuncture is a better way to treat dry-AMD (Age-related Macular Degeneration) compared to sham laser acupuncture, in the aspect of visual acuity.
- Trial name
- NCT06264947
- Testing
- laser acupuncture
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Age-Related Macular Degeneration
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
KH631 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain…
- Trial name
- NCT05672121
- Testing
- KH631
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
Diabetic Retinopathy
Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)
This will be a 24 month phase IV, randomised, prospective, multicentre, clinical trial of laser therapy to areas of peripheral retinal ischaemia combined with intravitreal aflibercept versus intravitreal aflibercept monotherapy.
- Trial name
- LADAMO (NCT02432547)
- Testing
- Aflibercept, Targeted laser therapy
- Where
- 2 sites in Australia
- Volunteers
- 48 people
- Sponsor
- University of Sydney
Giant Cell Arteritis, Visual Impairment
Visual Involvement in Giant Cell Arteritis
This observational study aims to enhance the description of the different ways Giant Cell Arteritis (GCA) affects vision. The latest technology and knowledge are used to improve how we diagnose and predict patient outcomes.
- Conditions
- Giant Cell Arteritis, Visual Impairment, Central Retinal Artery Occlusion, Anterior Ischemic Optic Neuropathy
- Trial name
- Visu-GCA (NCT06500728)
- Testing
- Fluorescein and Indocyanine green Angiography, High-resolution Optical Coherence Tomography, Angio-Optical Coherence Tomography
- Where
- Italy
- Volunteers
- 762 people
- Sponsor
- ASST Fatebenefratelli Sacco
Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
To evaluate and compare two individualised ranibizumab treatment regimens, differentiated by the definition of disease activity, which determines the treatment interval until the next injection.
- Trial name
- FLUID (NCT01972789)
- Testing
- Ranibizumab
- Where
- 16 sites in Australia
- Volunteers
- 349 people
- Sponsor
- Novartis Pharmaceuticals
Geographic Atrophy, Macular Degeneration
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
This study will assess the safety and efficacy of the brimonidine intravitreal implant in participants with geographic atrophy due to age-related macular degeneration.
- Trial name
- BEACON (NCT02087085)
- Testing
- 400 µg Brimonidine Implant
- Where
- 41 sites in United States, Australia and 4 more
- Volunteers
- 310 people
- Sponsor
- Allergan
Retinal Drusen, Age-related Macular Degeneration
Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)
The aim of this study is to evaluate the clinical benefits in visual function from dietary supplementation of the Lumega-Z carotenoid liquid-supplement in participants with drusen and at risk of AMD.
- Conditions
- Retinal Drusen, Age-related Macular Degeneration, Macular Degeneration
- Trial name
- AMD (NCT03946085)
- Testing
- Lumega-Z, AREDS2
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Guardion Health Sciences, Inc.
Macular Edema, Branch Retinal Vein Occlusion
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Branch retinal vein occlusion is a leading cause of vision loss. Treatment with ranibizumab (vascular endothelial growth factor (VEGF) inhibitor) on a monthly basis has been associated with improved vision results.
- Trial name
- Revolution (NCT01247220)
- Testing
- Ranibizumab, Peripheral Laser
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Retina Associates of Florida, P.A.
Ophthalmology, Macular Degeneration
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31…
- Trial name
- AURA (NCT01447043)
- Testing
- Ranibizumab
- Where
- 10 sites in Australia, Canada and 8 more
- Volunteers
- 2,609 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.